Clevidipine in the Treatment of Patients With Acute Hypertension and Intracerebral Hemorrhage (ACCELERATE)

PHASE3CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
HypertensionHemorrhage
Interventions
DRUG

clevidipine

"Clevidipine injectable emulsion (0.5 mg/mL) in 20% lipid emulsion in 100 mL bottles was administered intravenously to all patients via a single dedicated line.~Clevidipine was infused at an initial rate of 2.0 mg/h for the first 1.5 minutes. Thereafter, titration to higher infusion rates were to be attempted as needed to obtain the target systolic blood pressure (SBP) range (SBP ≤160 mmHg to ≥140 mmHg). Titration to effect was to proceed by doubling the dose every 1.5 minutes, up to a maximum of 32.0 mg/h, until the desired effect (SBP within the target range) was attained. The clevidipine infusion rate could be increased or decreased to maintain systolic blood pressure for up to a maximum of 96 hours."

Trial Locations (17)

10032

Columbia University Medical Center, New York

19107

Thomas Jefferson University Stroke Research, Philadelphia

21287

The John Hopkins Hospital, Baltimore

27405

Guilford Neurologic - Moses H Cone Health System, Greensboro

27710

Duke University Medical Center, Durham

29425

Medical University of South Carolina, Charleston

43210

The Ohio State University, Columbus

44195

Cleveland Clinic Hospitals, Cleveland

48202

Henry Ford Hospital, Detroit

84157

Intermountain Medical Center, Murray

96813

The Queens Medical Center, Honolulu

20010-2975

Washington Hospital Center, Washington D.C.

04102

Maine Medical Center, Portland

78229-3900

The University Health Science Center at S.A., San Antonio

D-04103

Universitätsklinikum Leipzig, Liebigstraße 22a

D91054

Universitatsklinikum Erlangen, Erlangen

D69120

Universitatsklinikum Heidelberg, Heidelberg

Sponsors
All Listed Sponsors
lead

The Medicines Company

INDUSTRY